About Andromeda-Shock 2
Background
I. Introduction
Septic shock is associated with a high mortality risk related to progressive tissue hypoperfusion [1]. However, despite extensive research on the best monitoring and resuscitation strategies, many uncertainties remain. Over-resuscitation, particularly when inducing fluid overload, might contribute to a worse outcome [2]. Fluid overload more likely occurs when fluids are administered to fluid unresponsive patients, but also when inappropriate resuscitation goals are pursued, or a “one-size-fits-all” strategy is followed [3].
Study protocol
1. Study design
1.1 Design
ANDROMEDA-SHOCK-2 will be multicentre, open-label, investigator-led randomized controlled trial conducted under supervision of an independent Data Safety Monitoring Board (DSMB). Recruited patients will be randomized to intervention arm (CRT-P) or usual care (UC).
ANDROMEDA-SHOCK 2 